Article
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC.
Scientific reports - 4 Jan 2024
De Rosa Caterina, De Rosa Viviana, Tuccillo Concetta, Tirino Virginia, Amato Luisa, Papaccio Federica, Ciardiello Davide, Napolitano Stefania, Martini Giulia, Ciardiello Fortunato, Morgillo Floriana, Iommelli Francesca, Della Corte Carminia Maria
Abstract excerpt
Osimertinib is a third-generation tyrosine kinase inhibitor clinically approved for first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC) patients. Although an impressive drug response is initially observed, in most of tumors, resistance occurs after different time and an alternative therapeutic strategy to induce regression disease is currently lacking. The hyperactivation of MEK/MAPKs, is one...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.